BD Veritor™ System
for SARS-CoV-2
For fast, clear and reliable COVID-19 results, when you need them the most.
Discover the portable, easy-to-use BD Veritor™ Plus System. It provides reliable results in just 15 minutes.1
When your patients need reliable, rapid COVID-19 testing, turn to the BD Veritor™ Plus System. It offers dependable results at the point of care in a simple-to-operate portable instrument.
Clinical performance vs RT-PCR
| PPA† | NPA‡ | Results in |
COVID-19 (SARS-CoV-2) | 84% (95% C.I. 77.2%-89.1%) | 99.7% (95% C.I. 99.0%-99.9%) |
15 minutes
|
COVID-19 results in 15 minutes
†positive percent agreement
‡negative percent agreement
Ordering information | Cat no. | Qty |
BD Veritor™ System SARS-CoV-2 | 256092 | 30 tests |
BD Veritor™ Plus Analyzer | 256066 | 1 unit |
Get more answers with every sample.
Simplifies the testing process
- May reduce manual test processing errors with easy operations and single-button functionality.
- Provides intuitive sample processing with prefilled, unitized tubes.
Delivers workflow efficiency
Adapts easily to your workflow by offering two operational modes:
- Walk away: Selected by double-clicking the power button, insert the test device into the Analyzer immediately after the sample has been added. The Analyzer will incubate for the appropriate time for each assay, then perform the analysis and display the test result. This allows staff to perform other duties while the sample incubates.
- Analyze now: The test device is inserted into the Analyzer after the recommended incubation time for each assay is complete, allowing for specimens to be processed in batches.** The Analyzer then performs the analysis and displays the test result.
Provides results traceability
- Captures or downloads the lot number, patient/specimen ID, operator ID, and test records using the BD Veritor™ InfoWifi module (optional add-on feature).
Achieves reliable, rapid results
- Displays easy-to-read digital results for COVID-19 in 15 minutes1 : “CoV2: +” for positive; “CoV2: –” for negative.
- Provides clear, objective results by correcting for nonspecific binding and detecting faint lines not recognized by the unaided eye.1
Contact a Sales Representative to get your organization’s
diagnostic testing program started today
How It Works
The BD Veritor™ Plus System provides an easy sample-collection process that can be incorporated across a variety of clinical settings.
Step 1: Collect sample
Step 2: Mix the swab with the reagent vial
Step 3: Prepare assay with the sample
Step 4: Run the test
Step 5: Insert the cartridge and read the results
BD Veritor™ Plus System Support & Training
See how BD supports you with tools, education, and training—enabling a streamlined point-of-care experience for those you serve, and confidence in your results.
Professional Care Testing
The BD Veritor™ Plus System enhances point-of-care testing for COVID-19, Flu A+B, COVID-19 & Flu A+B,* RSV and Group A Strep, providing rapid diagnostic testing in a convenient, portable instrument.
1. BD Veritor™ System for SARS-CoV-2. Package insert. 500075511(01) Becton, Dickinson and Company.
BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA 800-638-8663
*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
**Any batch testing performed should be conducted at the discretion of the user, in accordance with local policies and clinical judgment.
BD, the BD Logo, and BD Veritor are trademarks of Becton, Dickinson and Company or its affiliates. © 2026 BD. All rights reserved.
bd.com